Glox Therapeutics
Latest round
- Seed
Last raised
- Nov 2023
Total raised
- $5.3M
Investors
- 2
About Glox Therapeutics
Based in Glasgow, UK, and co-founded by Daniel Walker (CSO), Colin Kleanthous (Head of Scientific Advisory board), and James Clark (CEO)in 2023, Glox Therapeutics Limited operates as a biotechnology research company specializing in precision antibiotics. The company, as of November 2023, is working on the development of engineered protein bacteriocins-based antibiotics targeting drug-resistant pathogenic bacteria. Glox offers a platform called Glox Discovery Platform which exploits protein bacteriocins from Gram-negative bacteria to create species-specific antibiotics, avoiding harm to the host microbiome. The platform as of November 2023, focuses on pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae, both on the WHO critical list, to address urgent needs, including ventilator-associated pneumonia. Some of the Glox’s Engineered protein bacteriocins include Glox001 and Glox002, which target P. aeruginosa in ventilator-associated pneumonia, to eliminate specific bacterial pathogens without affecting the normal microbiota.
Who invested in Glox Therapeutics
2 investors across 1 round
See all investors in Glox Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Nov 14, 2023
Amount
$5.3M
Investors
Questions about Glox Therapeutics
Who invested in Glox Therapeutics?
Glox Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Glox Therapeutics raised?
Glox Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Glox Therapeutics last raise money?
Glox Therapeutics's most recent round on record is a Seed, in Nov 2023.
What does Glox Therapeutics do?
Based in Glasgow, UK, and co-founded by Daniel Walker (CSO), Colin Kleanthous (Head of Scientific Advisory board), and James Clark (CEO)in 2023, Glox Therapeutics Limited operates as a biotechnology research company specializing in precision antibiotics.
Where is Glox Therapeutics headquartered?
Glox Therapeutics is headquartered in Glasgow, UK.
Which VCs invest in companies like Glox Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Glox Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Glox Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.